Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CAN 1012

Next Previous
Drug Profile

CAN 1012

Alternative Names: CAN-1012

Latest Information Update: 03 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CanWell Pharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Toll-like receptor 7 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 03 Apr 2026 Efficacy and adverse events data from phase I/II trial in Solid tumours presented at the 50th European Society for Medical Oncology Congress (ESMO-2025)
  • 19 Feb 2026 CAN 1012 is still in phase I trials for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Intratumoural, Injection) (NCT04987112) (CanWell Pharma pipeline, February 2026)
  • 13 Feb 2026 Providence Health & Services in collaboration with CanWell Pharma plans a phase I trial for Epithelial dysplasia, Ductal carcinoma and Breast carcinoma in situ in USA (Intralesional, Injection) in May 2026 (NCT07408856)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top